Detalles de la búsqueda
1.
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
Circulation
; 149(6): 450-462, 2024 02 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37952217
2.
Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Circulation
; 2024 Apr 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38583093
3.
Kidney Function, Albuminuria, and Risk of Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Am J Kidney Dis
; 83(3): 350-359.e1, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37777059
4.
Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia.
Diabetes Obes Metab
; 2024 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38618983
5.
Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials.
J Am Soc Nephrol
; 34(12): 1965-1975, 2023 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37876229
6.
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.
Circulation
; 145(19): 1460-1470, 2022 05 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35394821
7.
Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials.
Kidney Int
; 104(1): 181-188, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37119876
8.
Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial.
Cardiovasc Diabetol
; 22(1): 330, 2023 11 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38017482
9.
The importance of targeting multiple risk markers in patients with type 2 diabetes: A post-hoc study from the CANVAS programme.
Diabetes Obes Metab
; 25(6): 1638-1645, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36782264
10.
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials.
Diabetes Obes Metab
; 25(8): 2331-2339, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37184050
11.
Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials.
Diabetes Obes Metab
; 25(11): 3327-3336, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37580309
12.
The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial.
Diabetes Obes Metab
; 25(12): 3724-3735, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37671609
13.
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials.
Diabetes Obes Metab
; 25(8): 2151-2162, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37161691
14.
Blood Pressure Effects of SGLT2 Inhibitors: Mechanisms and Clinical Evidence in Different Populations.
Curr Hypertens Rep
; 25(12): 429-435, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37948021
15.
Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression.
J Am Soc Nephrol
; 33(2): 291-303, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34862238
16.
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial.
Circulation
; 143(18): 1735-1749, 2021 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33554616
17.
Chronic kidney disease.
Lancet
; 398(10302): 786-802, 2021 08 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-34175022
18.
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial.
Diabetes Obes Metab
; 24(6): 1072-1083, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35166429
19.
Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis.
Diabetes Obes Metab
; 24(10): 1927-1938, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35589614
20.
Risk factors for incident kidney disease in older adults: an Australian prospective population-based study.
Intern Med J
; 52(5): 808-817, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33012112